Human  ||| S:0 E:6 ||| JJ
liver  ||| S:6 E:12 ||| JJ
rate-limiting  ||| S:12 E:26 ||| JJ
enzymes  ||| S:26 E:34 ||| NNS
influence  ||| S:34 E:44 ||| VBP
metabolic  ||| S:44 E:54 ||| JJ
flux  ||| S:54 E:59 ||| NN
via  ||| S:59 E:63 ||| IN
branch  ||| S:63 E:70 ||| NN
points  ||| S:70 E:77 ||| NNS
and  ||| S:77 E:81 ||| CC
inhibitors  ||| S:81 E:92 ||| JJ
Rate-limiting  ||| S:92 E:106 ||| JJ
enzymes ||| S:106 E:113 ||| NN
,  ||| S:113 E:115 ||| ,
because  ||| S:115 E:123 ||| IN
of  ||| S:123 E:126 ||| IN
their  ||| S:126 E:132 ||| PRP$
relatively  ||| S:132 E:143 ||| RB
low  ||| S:143 E:147 ||| JJ
velocity ||| S:147 E:155 ||| NN
,  ||| S:155 E:157 ||| ,
are  ||| S:157 E:161 ||| VBP
believed  ||| S:161 E:170 ||| VBN
to  ||| S:170 E:173 ||| TO
influence  ||| S:173 E:183 ||| VB
metabolic  ||| S:183 E:193 ||| JJ
flux  ||| S:193 E:198 ||| NN
in  ||| S:198 E:201 ||| IN
pathways ||| S:201 E:209 ||| NN
.  ||| S:209 E:211 ||| .
To  ||| S:211 E:214 ||| TO
investigate  ||| S:214 E:226 ||| VB
their  ||| S:226 E:232 ||| PRP$
regulatory  ||| S:232 E:243 ||| JJ
role  ||| S:243 E:248 ||| NN
in  ||| S:248 E:251 ||| IN
metabolic  ||| S:251 E:261 ||| JJ
networks ||| S:261 E:269 ||| NNS
,  ||| S:269 E:271 ||| ,
we  ||| S:271 E:274 ||| PRP
look  ||| S:274 E:279 ||| VBP
at  ||| S:279 E:282 ||| IN
the  ||| S:282 E:286 ||| DT
global  ||| S:286 E:293 ||| JJ
organization  ||| S:293 E:306 ||| NN
and  ||| S:306 E:310 ||| CC
interactions  ||| S:310 E:323 ||| NNS
between  ||| S:323 E:331 ||| IN
rate-limiting  ||| S:331 E:345 ||| JJ
enzymes  ||| S:345 E:353 ||| NN
and  ||| S:353 E:357 ||| CC
compounds  ||| S:357 E:367 ||| JJ
such  ||| S:367 E:372 ||| JJ
as  ||| S:372 E:375 ||| IN
branch  ||| S:375 E:382 ||| NN
point  ||| S:382 E:388 ||| NN
metabolites  ||| S:388 E:400 ||| NNS
and  ||| S:400 E:404 ||| CC
enzyme  ||| S:404 E:411 ||| JJ
inhibitors  ||| S:411 E:422 ||| NN
in  ||| S:422 E:425 ||| IN
human  ||| S:425 E:431 ||| JJ
liver ||| S:431 E:436 ||| NN
.  ||| S:436 E:438 ||| .
Based  ||| S:438 E:444 ||| VBN
on  ||| S:444 E:447 ||| IN
96  ||| S:447 E:450 ||| CD
rate-limiting  ||| S:450 E:464 ||| JJ
enzymes  ||| S:464 E:472 ||| NN
and  ||| S:472 E:476 ||| CC
132  ||| S:476 E:480 ||| CD
branch  ||| S:480 E:487 ||| NN
point  ||| S:487 E:493 ||| NN
compounds  ||| S:493 E:503 ||| NN
from  ||| S:503 E:508 ||| IN
human  ||| S:508 E:514 ||| JJ
liver ||| S:514 E:519 ||| NN
,  ||| S:519 E:521 ||| ,
we  ||| S:521 E:524 ||| PRP
found  ||| S:524 E:530 ||| VBD
that  ||| S:530 E:535 ||| DT
rate-limiting  ||| S:535 E:549 ||| JJ
enzymes  ||| S:549 E:557 ||| NNS
surrounded  ||| S:557 E:568 ||| VBN
76.5 ||| S:568 E:572 ||| CD
%  ||| S:572 E:574 ||| NN
of  ||| S:574 E:577 ||| IN
branch  ||| S:577 E:584 ||| NN
points ||| S:584 E:590 ||| NNS
.  ||| S:590 E:592 ||| .
In  ||| S:592 E:595 ||| IN
a  ||| S:595 E:597 ||| DT
compound  ||| S:597 E:606 ||| JJ
conversion  ||| S:606 E:617 ||| NN
network  ||| S:617 E:625 ||| NN
from  ||| S:625 E:630 ||| IN
human  ||| S:630 E:636 ||| JJ
liver ||| S:636 E:641 ||| NN
,  ||| S:641 E:643 ||| ,
the  ||| S:643 E:647 ||| DT
128  ||| S:647 E:651 ||| CD
branch  ||| S:651 E:658 ||| NN
points  ||| S:658 E:665 ||| NNS
involved  ||| S:665 E:674 ||| VBN
showed  ||| S:674 E:681 ||| VBD
a  ||| S:681 E:683 ||| DT
dramatically  ||| S:683 E:696 ||| RB
higher  ||| S:696 E:703 ||| RBR
average  ||| S:703 E:711 ||| JJ
degree ||| S:711 E:717 ||| NN
,  ||| S:717 E:719 ||| ,
betweenness  ||| S:719 E:731 ||| JJ
centrality  ||| S:731 E:742 ||| NN
and  ||| S:742 E:746 ||| CC
closeness  ||| S:746 E:756 ||| JJ
centrality  ||| S:756 E:767 ||| NN
as  ||| S:767 E:770 ||| IN
a  ||| S:770 E:772 ||| DT
whole ||| S:772 E:777 ||| NN
.  ||| S:777 E:779 ||| .
Nearly  ||| S:779 E:786 ||| RB
half  ||| S:786 E:791 ||| NN
of  ||| S:791 E:794 ||| IN
the  ||| S:794 E:798 ||| DT
in  ||| S:798 E:801 ||| IN
vivo  ||| S:801 E:806 ||| JJ
inhibitors  ||| S:806 E:817 ||| NN
were  ||| S:817 E:822 ||| VBD
products  ||| S:822 E:831 ||| NNS
of  ||| S:831 E:834 ||| IN
rate-limiting  ||| S:834 E:848 ||| JJ
enzymes ||| S:848 E:855 ||| NN
,  ||| S:855 E:857 ||| ,
and  ||| S:857 E:861 ||| CC
covered  ||| S:861 E:869 ||| VBD
75.34 ||| S:869 E:874 ||| CD
%  ||| S:874 E:876 ||| NN
of  ||| S:876 E:879 ||| IN
the  ||| S:879 E:883 ||| DT
inhibited  ||| S:883 E:893 ||| JJ
targets  ||| S:893 E:901 ||| NNS
in  ||| S:901 E:904 ||| IN
metabolic  ||| S:904 E:914 ||| JJ
inhibitory  ||| S:914 E:925 ||| JJ
networks ||| S:925 E:933 ||| NNS
.  ||| S:933 E:935 ||| .
From  ||| S:935 E:940 ||| IN
global  ||| S:940 E:947 ||| JJ
topological  ||| S:947 E:959 ||| JJ
organization ||| S:959 E:971 ||| NN
,  ||| S:971 E:973 ||| ,
rate-limiting  ||| S:973 E:987 ||| JJ
enzymes  ||| S:987 E:995 ||| NN
as  ||| S:995 E:998 ||| IN
a  ||| S:998 E:1000 ||| DT
whole  ||| S:1000 E:1006 ||| JJ
surround  ||| S:1006 E:1015 ||| JJ
most  ||| S:1015 E:1020 ||| JJS
of  ||| S:1020 E:1023 ||| IN
the  ||| S:1023 E:1027 ||| DT
branch  ||| S:1027 E:1034 ||| NN
points ||| S:1034 E:1040 ||| NNS
;  ||| S:1040 E:1042 ||| :
so  ||| S:1042 E:1045 ||| RB
they  ||| S:1045 E:1050 ||| PRP
can  ||| S:1050 E:1054 ||| MD
influence  ||| S:1054 E:1064 ||| VB
the  ||| S:1064 E:1068 ||| DT
flux  ||| S:1068 E:1073 ||| NN
through  ||| S:1073 E:1081 ||| IN
branch  ||| S:1081 E:1088 ||| NN
points ||| S:1088 E:1094 ||| NNS
.  ||| S:1094 E:1096 ||| .
Since  ||| S:1096 E:1102 ||| IN
nearly  ||| S:1102 E:1109 ||| RB
half  ||| S:1109 E:1114 ||| NN
of  ||| S:1114 E:1117 ||| IN
the  ||| S:1117 E:1121 ||| DT
in  ||| S:1121 E:1124 ||| IN
vivo  ||| S:1124 E:1129 ||| JJ
enzyme  ||| S:1129 E:1136 ||| JJ
inhibitors  ||| S:1136 E:1147 ||| NNS
are  ||| S:1147 E:1151 ||| VBP
produced  ||| S:1151 E:1160 ||| VBN
by  ||| S:1160 E:1163 ||| IN
rate-limiting  ||| S:1163 E:1177 ||| JJ
enzymes  ||| S:1177 E:1185 ||| NN
in  ||| S:1185 E:1188 ||| IN
human  ||| S:1188 E:1194 ||| JJ
liver ||| S:1194 E:1199 ||| NN
,  ||| S:1199 E:1201 ||| ,
these  ||| S:1201 E:1207 ||| DT
enzymes  ||| S:1207 E:1215 ||| NN
can  ||| S:1215 E:1219 ||| MD
initiate  ||| S:1219 E:1228 ||| VB
inhibitory  ||| S:1228 E:1239 ||| JJ
regulation  ||| S:1239 E:1250 ||| NN
and  ||| S:1250 E:1254 ||| CC
then  ||| S:1254 E:1259 ||| RB
influence  ||| S:1259 E:1269 ||| VB
metabolic  ||| S:1269 E:1279 ||| JJ
flux  ||| S:1279 E:1284 ||| NN
through  ||| S:1284 E:1292 ||| IN
their  ||| S:1292 E:1298 ||| PRP$
natural  ||| S:1298 E:1306 ||| JJ
products ||| S:1306 E:1314 ||| NNS
.  ||| S:1314 E:1316 ||| .
